# US 2010/0168046 A1 · Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168046 A1
- Document ID: US20100168046A1
- Status: Published application
- Kind: A1
- Application number: 12/720,557
- Filed: 2010-03-09
- Published: 2010-07-01
- Earliest claimed: 2007-05-04
- Assignees: Nereus Pharmaceuticals, Inc.
- Inventors: Michael Palladino
- Web page: https://patentgrep.com/patent/US20100168046A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/133: having hydroxy groups, e.g. sphingosine
- A61K 31/4409: only substituted in position 4, e.g. isoniazid, iproniazid
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/65: Tetracyclines
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 38/06: Tripeptides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/12: Antidiarrhoeals
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 27/16: Otologicals
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/08: for leprosy
- A61P 31/16: for influenza or rhinoviruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are methods of treating infectious diseases comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent.

## Claims

### Claim 1

A method of preventing mycobacterium tuberculosis from becoming multi-drug resistant comprising administering to an animal infected with said mycobacterium tuberculosis Salinosporamide A:

### Claim 2 (depends on 1)

The method of claim 1, further comprising co-administering one or more anti-infective agent(s).

### Claim 3 (depends on 2)

The method of the claim 2, wherein the one or more anti-infective agent(s) is selected from the group consisting of isoniazid, rifampin, ethambutol, pyrazinamide, rifater, streptomycin, rifapentine and epoxomicin.

### Claim 4

A method of treating drug resistant Tuberculosis comprising administering to an animal in need thereof. Salinosporamide A:

### Claim 5 (depends on 4)

The method of claim 4, wherein the bacteria causing Tuberculosis is selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium Bovis, Mycobacterium africanum and Mycobacterium microti.

### Claim 6 (depends on 5)

The method of claim 5, further comprising co-administering one or more anti-infective agent(s).

### Claim 7 (depends on 6)

The method of the claim 6, wherein the anti-infective agent(s) is selected from the group consisting of isoniazid, rifampin, ethambutol, pyrazinamide, rifater, streptomycin, rifapentine and epoxomicin.

### Claim 8 (depends on 7)

The method of the claim 7, wherein the anti-infective agent is isoniazid.

### Claim 9 (depends on 8)

The method of claim 8, wherein the bacteria causing Tuberculosis is Mycobacterium tuberculosis.

### Claim 10

A method of treating an infectious disease comprising administering to an animal in need thereof a compound having the structure of any one of Formulas I and II, or a pharmaceutically acceptable salt thereof:
wherein:
the dashed lines represent a single or a double bond;
each R1 is separately a hydrogen, a halogen, a cyano, a nitro, an azido, a hydroxy, or a thiocyano, or selected from the group consisting of optionally substituted: C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, phenyl, cycloalkylacyl, alkylthio, arylthio, oxysulfonyl, carboxy, thio, sulfoxide, sulfone, sulfonate esters, boronic acids and esters, and halogenated alkyl including polyhalogenated alkyl;
n is 1 or 2, where if n is 2, then each R1 can be the same or different;
m is 1 or 2, where if m is 2, then each R4 can be the same or different;
R2 is a hydrogen, a halogen, a cyano, a nitro, an azido, a hydroxy, or a thiocyano, or selected from the group consisting of optionally substituted: C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, phenyl, cycloalkylacyl, alkylthio, arylthio, oxysulfonyl, carboxy, thio, sulfoxide, sulfone, sulfonate esters, boronic acids and esters, and halogenated alkyl including polyhalogenated alkyl;
R3 is a halogen or selected from the group consisting of optionally substituted C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, and halogenated alkyl including polyhalogenated alkyl;
each of E1, E3, E4 and E5 is an optionally substituted heteroatom;
E2 is an optionally substituted heteroatom or —CH2— group;
each R4 is separately a halogen, a cyano, a nitro, an azido, or a thiocyano, or selected from the group consisting of optionally substituted C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, hydroxy, aminocarbonyl, aminocarbonyloxy, phenyl, cycloalkylacyl, alkylthio, arylthio, oxysulfonyl, carboxy, thio, sulfoxide, sulfone, sulfonate esters, boronic acids and esters, and halogenated alkyl including polyhalogenated alkyl; and
wherein the infectious disease is Tuberculosis.

### Claim 11 (depends on 10)

The method of claim 10, wherein the compound is Salinosporamide A:

### Claim 12 (depends on 11)

The method of claim 11, wherein the bacteria causing Tuberculosis is selected from the group consisting of Mycobacterium Bovis, Mycobacterium africanum and Mycobacterium microti.

### Claim 13 (depends on 11)

The method of claim 11, wherein the bacteria causing Tuberculosis is Mycobacterium tuberculosis.

### Claim 14 (depends on 13)

The method of claim 13, further comprising co-administering one or more anti-infective agent(s).

### Claim 15 (depends on 14)

The method of the claim 14, wherein the anti-infective agent(s) is selected from the group consisting of isoniazid, rifampin, ethambutol, pyrazinamide, rifater, streptomycin, rifapentine and epoxomicin.

### Claim 16 (depends on 15)

The method of the claim 15, wherein the anti-infective agent(s) is isoniazid.

### Claim 17 (depends on 10)

The method of claim 10, wherein the animal is a human.

### Claim 18 (depends on 17)

The method of claim 17, wherein the compound is Salinosporamide A:

### Claim 19 (depends on 18)

The method of claim 18, further comprising co-administering one or more anti-infective agent(s).

### Claim 20 (depends on 19)

The method of the claim 19, wherein the anti-infective agent(s) is selected from the group consisting of isoniazid, rifampin, ethambutol, pyrazinamide, rifater, streptomycin, rifapentine and epoxomicin.
